The human MSH2/6 complex is essential for mismatch recognition during the repair of replication errors. Although mismatch repair components have been implicated in DNA homologous recombination repair, the exact function of hMSH2/6 in this pathway is unclear. Here, we show that the recombinant hMSH2/6 protein complex stimulated the ability of the Bloom's syndrome gene product, BLM, to process Holliday junctions in vitro, an activity that could also be regulated by p53. Consistent with these observations, hMSH6 colocalized with BLM and phospho-ser15-p53 in hydroxyurea-induced RAD51 nuclear foci that may correspond to the sites of presumed stalled DNA replication forks and more likely the resultant DNA double-stranded breaks. In addition, we show that hMSH2 and hMSH6 coimmunoprecipitated with BLM, p53, and RAD51. Both the number of RAD51 foci and the amount of the BLM-p53-RAD51 complex are increased in hMSH2-or hMSH6-deficient cells. These data suggest that hMSH2/6 formed a complex with BLM-p53-RAD51 in response to the damaged DNA forks during double-stranded break repair.
Introduction
The DNA mismatch repair (MMR) pathway maintains genomic integrity by correcting DNA replication errors. The homologs of bacterial MutS and MutL, which play key roles in mismatch recognition and repair initiation, have been identified in yeast and mammalian cells (Kolodner, 1996; Modrich and Lahue, 1996; Jiricny, 1998; Buermeyer et al., 1999; Harfe and Jinks-Robertson, 2000) . MSH2 and MSH6, homologs of MutS, form a heterodimer also known as MutSa, which functions in the repair of single-base mismatches and small insertion-deletion loops (Drummond et al., 1995; Palombo et al., 1995; Acharya et al., 1996; Genschel et al., 1998) . MMR components have participated in the processing of DNA damage and suppressed homologous recombination repair (HRR) (de Wind et al., 1995 (de Wind et al., , 1999 Modrich and Lahue, 1996; Evans et al., 2000; Elliott and Jasin, 2001) , as shown by the hyper-recombinational phenotype in the MSH2-or MSH6-deficient cells (de Wind et al., 1995 (de Wind et al., , 1999 . The MSH2/6 complex can bind to Holliday junctions (HJ) and may play a direct role in the HRR (Marsischky et al., 1999) .
BLM is an ATP-dependent DNA helicase, and germline mutations in the BLM gene cause Bloom's syndrome, a cancer predisposition disorder associated with genomic instability (van Brabant et al., 2000) . The mutations disrupt its helicase activity, indicating the contribution of the helicase function to the phenotypic traits associated with this hereditary disease (Chakraverty and Hickson, 1999; van Brabant et al., 2000) . BLM is a structure-specific DNA helicase (Mohaghegh et al., 2001 ) that may be involved in HRR through an ability to promote the ATP-dependent translocation of HJ, a function that may suppress inappropriate DNA recombination in vivo (Karow et al., 2000) . RAD51 and BLM form a complex that colocalizes at nuclear foci in cells arrested in the S phase by the replication inhibitors, aphidicolin or hydroxyurea (HU) (Bischof et al., 2001; Wu et al., 2001; Sengupta et al., 2003) . HU treatment leads to DNA double-stranded breaks (DSB) accumulation, RAD51 focus formation, and the stimulation of RAD51-dependent gene conversion (Saintigny et al., 2001) . BLM associates with other proteins involved in DNA repair such as BRCA1, ATM, hMLH1, hMSH2, hMSH6, and replication factor C to form a complex called BASC that was isolated from p53-deficient HeLa cells (Wang et al., 2000) . BLM binds directly to hMLH1, but is not required for DNA MMR (Langland et al., 2001; Pedrazzi et al., 2001) . The Saccharomyces cerevisiae homolog of BLM, SGS1, suppresses genomic instability and homologous recombination (Myung et al., 2001) . Epistasis analysis shows that SGS1 is redundant with DNA MMR for suppressing recombination between divergent DNA sequences. SGS1 is an integral component of the S-phase checkpoint response in yeast and has been directly implicated in S-phase checkpoint activation of signal transduction cascades (Frei and Gasser, 2000) . p53 binds to HJ and DNA containing mismatched and bulged bases (Lee et al., 1997; Degtyareva et al., 2001) , and regulates BLM to disrupt HJ (Yang et al., 2002) . Moreover, p53 physically and functionally interacts with BLM during DNA damage-induced apoptosis . p53 accumulates, but is impaired in its transcriptional and cell cycle checkpoint functions, when DNA synthesis is blocked by HU (Gottifredi et al., 2001) . Loss of either p53 or BLM is accompanied by an increase in the rate of HRR (Bertrand et al., 1997; Mekeel et al., 1997; Dudenhoffer et al., 1999; Gebow et al., 2000; Wu et al., 2001) . Bloom syndrome cells undergo p53-dependent apoptosis and delayed assembly of BRCA1 and NBS1 repair complexes at stalled replication forks (Davalos and Campisi, 2003) . p53 colocalizes with MSH2 associated with recombinative repair complexes (Zink et al., 2002) . We have recently shown that BLM regulates p53 localization to the sites of double-stranded DNA breaks, and a p53 deficiency further enhances HRR, including sister chromatid exchanges in Bloom's syndrome cells (Linke et al., 2003; Sengupta et al., 2003) . Based on these studies, we hypothesize that hMSH2/6, BLM, and p53 may function together in regulating RAD51-dependent HHR.
Results
hMSH6 colocalizes with BLM, p53, and RAD51, and hMSH2/6 regulates the number of RAD51 foci
We investigated whether the hMSH2/6 complex is directly involved in HRR through its physical and functional interactions with BLM, p53, and RAD51. Indirect immunofluorescence and confocal analyses showed that hMSH6 was localized to nuclear foci in normal fibroblasts (WI-38) (Figure 1 ). Approximately 20% of these foci colocalized with either BLM or RAD51 (Figure 1a-b) . At most, there was a two-fold increase in these colocalizations after treating the cells with HU. About half of the HU-treated cells displayed phospho-ser15-p53 nuclear foci (Figure 1c ), but these foci were not observed in the untreated cells. Approximately 44% of the phospho-ser15-p53 foci in HUtreated cells were sites of hMSH6 accumulation. As RAD51 localizes at nuclear foci that are thought to represent sites of recombinational repair (Wu et al., 2001) , we determined the role of hMSH2/6 in RAD51 localization at nuclear foci. About 60% of HEC59 (hMSH2
) and 56% of HCT15 (hMSH6 À/À ) cells contained RAD51 foci without exposure to exogenous agents (Figure 2 ). In contrast, in HEC59 þ Ch2 and (Figure 2 ). We also examined BLM foci in MMR-deficient and corrected cells. The number of BLM foci and strength of immunofluorescence signals were not different between HEC59 and HEC59 þ Ch2, HCT15 and HCT15 þ Ch2, with or without HU treatment. These untreated cells exhibited about 6-15 BLM foci per cell. The number of BLM foci increased to 25-50 per cell after HU treatment. In addition, hMSH6 foci also were similar in BS fibroblasts (GM03509) and chromosome 15-corrected BS fibroblasts GM03509 (data not shown).
hMSH2/6 interact with BLM, p53, and RAD51
To further explore the effect of hMSH2/6 on BLM-RAD51-mediated recombinational repair, we determined the interactions of these proteins in cells. Cell lysates, prepared from either untreated or treated (HU) normal human lymphoblastoid cells (GM01310) with DNase I treatment, were then subjected to immunoprecipitation with antibodies that specifically recognize BLM, p53, or RAD51. Bound proteins were analysed, following gel electrophoresis, by Western blotting with the anti-MSH2 or anti-MSH6 antibody. BLM, p53, and RAD51 coimmunoprecipitated with hMSH2 and hMSH6, and these associations increased by a small degree after HU treatment (Figure 3a) . To further confirm the association of the hMSH2/6 complex with BLM, immunoprecipitation of hMSH6 brought down BLM with nuclear extracts from HeLa cells (Figure 3b ), but could not find these associations in normal human lymphoblastoid cells, HEC59 þ ch2, or HCT15 þ ch2 cells. We found that the proportion of RAD51 that coimmunoprecipitated with BLM and p53 was increased in hMSH2-and hMSH6-deficient cells when compared with the cells genetically rescued with chromosome 2 (Figure 4a ). Further increases in the coimmunoprecipitation of RAD51 with BLM and p53 were detected in HU-treated cells. RAD51 showed a similar expressed level in these cells with or without HU treatment ( Figure  4b ), indicating that RAD51 may be redistributed in these cells and with HU treatment. There was also no difference of RAD51 amount by immunoprecipitation with anti-RAD51 antibody among these cells (Figure 4c , data not shown). Competitive peptides blocked the coimmunoprecipitation of p53 and BLM with the RAD51 antibody, excluding the possibility that the coimmunoprecipitations were nonspecific (Figure 4d ).
hMSH2/6 stimulate BLM-mediated disruption of HJ in vitro BLM promotes HJ branch migration (Karow et al., 2000) , a step often required during the processing of DNA lesions at stalled DNA replication sites. We investigated whether the hMSH2/6 complex modulates BLM activity on HJ by using a radiolabeled HJ mimic, a synthetic X-junction (X-12), as a substrate (McGlynn and Lloyd, 1999) . As shown previously (Karow et al., 2000; Yang et al., 2002) , purified recombinant BLM disrupted the X-junction (Figure 5a ). hMSH2/6 stimulated BLM-mediated disruption in a dose-dependent manner. The strong signals of disrupted products were observed at only a modest excess of protein (20-40 nM of hMSH2/6) over the DNA substrate (10 nM). At a 40 nM concentration, hMSH2/6 enhanced BLM helicase activity on the X-junction (10 nM) approximately sevenfold. We also used another source of hMSH2/6 proteins (a gift from JD Griffith) and observed similar results. hMSH2/6 alone had neither helicase activity nor nuclease activity for the X-junction, dsDNA, and ssDNA under standard helicase reaction conditions (Figure 5a ). Unlike hMSH2/6, the p53 protein attenuated BLM helicase unwinding of the X-junction (Figure 5b) . Furthermore, p53 inhibited the ability of hMSH2/6 to stimulate the BLM helicase, implying that p53 can function as an opposing cofactor in the BLMhMSH2/6 DNA substrate complex. The ability of hMSH2/6 and p53 to regulate BLM helicase activity may be caused by hMSH2/6 and p53 altering the binding affinity of BLM for HJ. To test this hypothesis, an ELISA assay was used. p53 inhibited BLM binding to X-junctions (X-12) in a dose-dependent manner ( Figure 6 ). In contrast, hMSH2/6 stimulated BLM binding to X-junctions. Statistical analysis showed a significant difference of this BLM binding increase between hMSH2/6 and BSA control group from 20 to 80 nM concentrations (Po0.01). Our previous report showed that 273p53, a recombinant p53 mutant protein that corresponds to a hotspot mutant found in human cancer, did not inhibit the disruption of X-junctions by BLM (Yang et al., 2002) . Consistent with these data, 273p53 did not affect BLM binding to X-junctions by ELISA. These data suggest that hMSH2/6 and p53 physically interact with BLM and this interaction may play a role in the regulation of its helicase activity. (d) The peptide against which RAD51 antibody was raised as a control for RAD51, BLM, and p53 IP Figure 5 Effects of hMSH2/6 and p53 on BLM-mediated Xjunction disruption (a) hMSH2/6 enhanced BLM disruption of an X-junction. The helicase assay (20 ml) used 6 nM of BLM protein with the X-junction (10 nM) in the absence or presence of the indicated concentrations of hMSH2/6 protein complex. The appearance of the faster migrating two-armed products (branch migration) and ssDNA species indicates disruption of the Xjunction. m, heat-denatured control. Lane 9, heated BLM and hMSH2/6, then cooled to 371C and incubated with X-junction. Quantification of products included two-armed and ssDNA species. (b) Effect of p53 on X-junction disruption. BLM was incubated with the X-junction (10 nM) in the presence of hMSH2/6 without p53 or with p53 under standard helicase reaction conditions hMSH2/6 regulates BLM helicase Q Yang et al
Discussion
Several lines of evidence show that HRR is clearly involved in the repair of DNA DSB. Impairment of this repair mechanism leads to the loss of genomic integrity, one of the hallmarks of cancer (Khanna and Jackson, 2001; Thompson and Schild, 2001) . In mammalian cells, about half of all DNA DSB are repaired by mechanisms involving HRR (Liang et al., 1998) . As cell extracts lacking functional BLM helicase activity are competent for DNA MMR (Langland et al., 2001) , the interaction of BLM with mismatch proteins may be significant for specific DNA events, for example, HRR, independent of the repair of single DNA mismatches. Studies using a yeast model system suggest that MSH2 and the SGS1 helicase play a significant role in HRR (Marsischky et al., 1999; Evans et al., 2000; Frei and Gasser, 2000; Myung et al., 2001) . In this report, we demonstrate that hMSH2/6 stimulated BLM-mediated disruption of HJ in vitro. hMSH2/6 and p53 physically interacted with BLM and regulated its binding ability to HJ. As shown in our previous report (Yang et al., 2002) , the inhibition of BLM helicase activity by p53 is mediated by its direct interaction with BLM and not with the HJ substrate. Consistent with these findings in vitro, endogenous hMSH6 colocalized with p53, BLM, and RAD51 foci at DSB sites in vivo. Not only the number of RAD51 foci, but also the amount of the BLM-p53-RAD51 complex was increased in hMSH2-or hMSH6-deficient cells. There are at least two different possibilities for increased complexes observed in the immunoprecipitation experiments performed with MMR-deficient cells. The first is related to the model just presented -more mismatches in the MMR-deficient cells led to more complexes being formed, consistent with more RAD51 foci. The second is that there are many different types of complexes formed among the proteins studied here and that eliminating a protein by mutation simply alters the protein pool composition so that some complexes are not formed, allowing other complexes to be formed at higher levels. RAD51 is a key recombinase in the HRR. The foci formation of RAD51 increases in MSH2-deficient cells 0-2 h after IR treatment and attenuates at later time points, suggesting that MSH2 is required both for successful DSB repair in the G2 phase of the cell cycle and for the maintenance of the early-G2 arrest, but not to sense IR-induced DNA damage and initiate the early phases of HRR (Franchitto et al., 2003) . HU specifically inhibits the elongation of replication. RAD51 foci increase during HU treatment from 3 to 24 h (Saintigny et al., 2001) . We observed that MMR-deficient cells display an elevated RAD51 foci formation and higher induction of RAD51 foci in cells arrested in the S phase, following HU 14 h treatment. Thus, the absence of hMSH2/6 could result in both spontaneous DNA damage and uncontrolled recombination events leading to the RAD51 focus-forming activity.
Another model for the association of BLM, p53, RAD51, and MMR proteins is that RAD51 recruits BLM to remove HJ during HRR (Wu et al., 2001) . As MSH2/6 and p53 can each bind to HJ, one or both of these may also directly position BLM at the HRR sites. Although BLM is required for efficiently recruiting p53 to sites of DNA DSB (Sengupta et al., 2003) , p53 may enhance the assembly of the HRR multiprotein complex, upon which its inhibition of BLM helicase activity would then be over-ridden by hMSH2/6. p53 may also 'govern' the prorecombinogenic function of RAD51 through direct binding and by modulating its assembly (Linke et al., 2003; Sengupta et al., 2003) . The posttranslational modification of p53 and the apoptotic response to DNA mismatches generated by alkylating agents has been previously shown to be dependent on functional hMSH2/6 (Duckett et al., 1999; Hickman and Samson, 1999) . hMSH2 expression is also upregulated by p53 (Warnick et al., 2001) . These data further implicate the involvement of hMSH2/6 in multiple cellular stress response pathways. Stagljar and coworkers have performed similar studies using HeLa cells and showed the BLM colocalization with MSH6, the reciprocal coimmunoprecipitation of BLM with MSH6, and the in vitro binding of the recombinant proteins (Pedrazzi et al., 2003) . Lesion binding by p53 represents an important biological feature of this protein. hMSH2/6 enhances p53 binding to HJ , suggesting that hMSH/6 appears to be either recruiting p53 to lesion sites or stabilizing p53/DNA interactions in some manner. To support the binding model, p53, like classical MMR factors, checks the fidelity of homologous recombination processes by specific mismatch recognition (Dudenhoffer et al., 1998) . Further investigations are required to define the assembly and function of the multiprotein machines responsible for HRR and MMR.
Genomic instability can be manifested either at the nucleotide or at the chromosomal level. Instability at the nucleotide level can be found in hereditary nonpolyposis Figure 6 Binding ability of BLM to X-junction DNA by ELISA. Reacti-Bindt NeutrAvidint-coated polystyrene plates (PIERCE) were incubated with Biotin-labeled X-junctions (100 nM), and then incubated with 12 nM BLM protein in the presence or absence of hMSH2/6 and p53 in 100 ml reaction. Bound BLM protein was detected using anti-BLM antibody. Student's t-test was used for analysing the statistical significance between hMSH2/6 and BSA control from 20 to 80 nM concentrations (Po0.01), and p53 and BSA or 273p53 in all concentrations (Po0.01) hMSH2/6 regulates BLM helicase Q Yang et al colorectal cancer (HNPCC), where defects in MMR genes including hMSH2, hMSH6, hMLH1, and hPMS2 cause widespread mutation (Kolodner, 1996; Modrich and Lahue, 1996; Jiricny, 1998; Buermeyer et al., 1999; Harfe and Jinks-Robertson, 2000) . Recent studies showed a high rate of CAD gene amplification in hMLH1-and hMSH6-deficient cells . These results indicate that hMSH2/6 may suppress inappropriate recombination and functions at several levels in the maintenance of genomic stability. Our studies reveal a possible dual function for hMSH2/6, in which its inactivation in HNPCC might lead to genomic instability and tumorigenesis by a novel mechanism.
Materials and methods
Cell culture, Western blot analyses, and immunoprecipitation HEC59, an endometrial tumor cell line, contains mutations in both alleles of hMSH2, and HCT15, a colon tumor cell line, contains mutations in hMSH6. Both cell lines introduced by the microtransfer method with a normal chromosome 2 (a gift from T Kunkel) have been described (Umar et al., 1997) . LiFraumeni fibroblasts (LFS041) were a gift from M Tainsky, and LFS041 þ p53 cells expressed Tet-regulated p53 cDNA (Bean and Stark, 2001 ). GM01310, a normal human lymphoblastoid cell line (LCL), and WI-38, normal human fibroblasts were obtained from the ATCC. Western blot analyses and immunoprecipitation were essentially as described previously (Spillare et al., 1999) . Briefly, cell extracts were prepared in lysis buffer containing 50 mM Tris-HCl (pH 7.5), 120 mM NaCl, 1% Nonidet P-40 with protease inhibitors. After treating with DNase I, 2 mg of cellular protein was immunoprecipitated by the appropriate antibodies and protein A/G beads. Proteins were separated by SDS-polyacrylamide gel and electrophoretically transferred onto nitrocellulose membranes, followed by Western blot analyses.
Proteins and antibodies
The hMSH2/6 protein was purified as described (Blackwell et al., 2001) . Recombinant hMSH2/6 preparations had a purity of 98% or better, were characterized by a 1 : 1 subunit stoichiometry, and were fully active in MMR as judged by in vitro complementation of nuclear extracts derived from MSH2-deficient human cells. Recombinant hexa-histidinetagged human BLM protein was purified as described previously (Karow et al., 1997) . Human p53 protein was generated from recombinant baculoviruses in Sf9 insect cells and purified using an anti-p53 antibody (PAb421) immunoaffinity column, as described previously (Bargonetti et al., 1991) . Anti-BLM antibody, C-18, was from Santa Cruz Biotechnology, and IHIC33 was prepared as described previously (Wu et al., 2000) . Anti-phospho-ser15-p53, anti-p53 (DO-1), and anti-RAD51 antibodies were from Oncogene Research Products. Anti-MSH2 antibody was obtained from BD Biosciences (Transduction Laboratories) and Calbiochem (Ab-2).
Anti-MSH6 antibody was obtained from BD Biosciences (Transduction Laboratories) and Serotech (21F10).
DNA substrates and helicase assay
The BLM helicase assay reactions (20 ml) contained the 32 Plabeled X-junction (10 nM) in 20mM Tris-HCl, pH 7.5, 1.25 mM MgCl 2 , 2mM ATP, 0.1 mg/ml BSA, and 1 mM DTT. The synthetic X-junction (four-arm junction, X-12) was prepared by annealing four 50-mer oligonucleotides as described previously (McGlynn and Lloyd, 1999) . Reactions were initiated by the BLM protein and incubated at 371C for 30 min. The products were separated by electrophoresis through 10% nondenaturing polyacrylamide gels at 41C, visualized using a PhosphorImager or film autoradiography, and signals were quantified using the ImageQuant software.
ELISA
Biotin-labeled 100 nM X-junctions (X-12) were incubated in the EMSA buffer (100 ml) in a Reacti-Bindt NeutrAvidintcoated polystyrene plate (PIERCE) for 30 min at 241C. BLM (6 nM) was preincubated with or without appropriate proteins in the same buffer (100 ml) for 10 min at 241C. The proteins were then added to prepared ELISA plates and incubated for another 20 min. Anti-BLM and secondary antibodies were added sequentially. Phosphatase substrate (Sigma) was incubated for 1 h at 371C. The OD 405 values, corrected for background with BSA, were expressed as the mean of three independent experiments.
Indirect immunofluorescence
Experiments were performed as described (Wu et al., 2000) . Briefly, confocal fluorescent images were collected with a BioRad MRC 1024 confocal scan head mounted on a Nikon Optiphot microscope with a Â 60 Zeiss LSM410. Z sections were captured at 0.5-mm intervals for each cell using LaserSharp software (Bio-Rad). Confocal Assistant software (Bio-Rad) was used to analyze. For quantitation of signal overlap, the Z sections of five random cells that were scored as containing foci were analysed and averaged with the Bio-Rad LaserSharp software. For conventional immunofluorescence microscopy, the cells were examined with a Zeiss Axioskop fluorescence microscope equipped with a CCD camera. Images were captured, pseudocolored, and merged using IPLab image analysis software. At least 100 cells were analysed for each experiment. The experiments were repeated at least three times. Colocalization in quantitative data indicates the percentage of the proteins that colocalize with each other [yellow/(yellow þ green) and yellow/(yellow þ red)]. For example, in Figure 1a , 25% of hMSH6 foci colocalized with BLM, whereas 18% of BLM foci colocalized with hMSH6 in untreated cells.
